|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang F, Zhou J, Zhang Y, Wang Y, Cheng L,
Bai Y and Ma H: The value of microRNA-155 as a prognostic factor
for survival in non-small cell lung cancer: A meta-analysis. PLoS
One. 10:e01368892015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Verdecchia A, Francisci S, Brenner H,
Gatta G, Micheli A, Mangone L and Kunkler I; EUROCARE-4 Working
Group, : Recent cancer survival in Europe: A 2000–02 period
analysis of EUROCARE-4 data. Lancet Oncol. 8:784–796. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen C, Zhao Z, Liu Y and Mu D:
MicroRNA-99a is downregulated and promotes proliferation, migration
and invasion in non-small cell lung cancer A549 and H1299 cells.
Oncol Lett. 9:1128–1134. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li Y, Li Y, Liu J, Fan Y, Li X, Dong M,
Liu H and Chen J: Expression levels of microRNA-145 and
microRNA-10b are associated with metastasis in non-small cell lung
cancer. Cancer Biol Ther. 17:272–279. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang Y, Yang X, Wu H, Zhou W and Liu Z:
MicroRNA-145 inhibits migration and invasion via inhibition of
fascin 1 protein expression in non-small-cell lung cancer cells.
Mol Med Rep. 12:6193–6198. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li D, Wei Y, Wang D, Gao H and Liu K:
MicroRNA-26b suppresses the metastasis of non-small cell lung
cancer by targeting MIEN1 via NF-κB/MMP-9/VEGF pathways. Biochem
Biophys Res Commun. 472:465–470. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gee GV, Koestler DC, Christensen BC,
Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA,
Kelsey KT and Marsit CJ: Downregulated microRNAs in the
differential diagnosis of malignant pleural mesothelioma. Int J
Cancer. 127:2859–2869. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Griffiths-Jones S, Grocock RJ, van Dongen
S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets
and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Donadeu FX, Schauer SN and Sontakke SD:
Involvement of miRNAs in ovarian follicular and luteal development.
J Endocrinol. 215:323–334. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liwak U, Faye MD and Holcik M: Translation
control in apoptosis. Exp Oncol. 34:218–230. 2012.PubMed/NCBI
|
|
14
|
Rutnam ZJ and Yang BB: The involvement of
microRNAs in malignant transformation. Histol Histopathol.
27:1263–1270. 2012.PubMed/NCBI
|
|
15
|
Joshi P, Middleton J, Jeon YJ and Garofalo
M: MicroRNAs in lung cancer. World J Methodol. 4:59–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen T, Gao F, Feng S, Yang T and Chen M:
MicroRNA-370 inhibits the progression of non-small cell lung cancer
by downregulating oncogene TRAF4. Oncol Rep. 34:461–468. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang H, Yan C, Shi X, Zheng J, Deng L,
Yang L, Yu F, Yang Y and Shao Y: MicroRNA-575 targets BLID to
promote growth and invasion of non-small cell lung cancer cells.
FEBS Lett. 589:805–811. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li D, Li DQ, Liu D and Tang XJ: miR-613
induces cell cycle arrest by targeting CDK4 in non-small cell lung
cancer. Cell Oncol (Dordr). 39:139–147. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cortinovis D, Monica V, Pietrantonio F,
Ceresoli GL, La Spina CM and Wannesson L: MicroRNAs in non-small
cell lung cancer: Current status and future therapeutic promises.
Curr Pharm Des. 20:3982–3990. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boeri M, Pastorino U and Sozzi G: Role of
microRNAs in lung cancer: microRNA signatures in cancer prognosis.
Cancer J. 18:268–274. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishijima N, Seike M, Soeno C, Chiba M,
Miyanaga A, Noro R, Sugano T, Matsumoto M, Kubota K and Gemma A:
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small
cell lung cancer cells. Int J Oncol. 48:937–944. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hou Y, Zhen J, Xu X, Zhen K, Zhu B, Pan R
and Zhao C: miR-215 functions as a tumor suppressor and directly
targets ZEB2 in human non-small cell lung cancer. Oncol Lett.
10:1985–1992. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou YL, Xu YJ and Qiao CW: miR-34c-3p
suppresses the proliferation and invasion of non-small cell lung
cancer (NSCLC) by inhibiting PAC1/MAPK pathway. Int J Clin Exp
Pathol. 8:6312–6322. 2015.PubMed/NCBI
|
|
25
|
Sun L, Wang Q, Gao X, Shi D, Mi S and Han
Q: MicroRNA-454 functions as an oncogene by regulating PTEN in
uveal melanoma. FEBS Lett. 589:2791–2796. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and
Liu JY: miR-454 prompts cell proliferation of human colorectal
cancer cells by repressing CYLD expression. Asian Pac J Cancer
Prev. 16:2397–2402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou L, Qu YM, Zhao XM and Yue ZD:
Involvement of miR-454 overexpression in the poor prognosis of
hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 20:825–829.
2016.PubMed/NCBI
|
|
28
|
Niu G, Li B, Sun J and Sun L: miR-454 is
down-regulated in osteosarcomas and suppresses cell proliferation
and invasion by directly targeting c-Met. Cell Prolif. 48:348–355.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Fang B, Zhu J, Wang Y, Geng F and Li G:
miR-454 inhibited cell proliferation of human glioblastoma cells by
suppressing PDK1 expression. Biomed Pharmacother. 75:148–152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fan Y, Xu LL, Shi CY, Wei W, Wang DS and
Cai DF: MicroRNA-454 regulates stromal cell derived factor-1 in the
control of the growth of pancreatic ductal adenocarcinoma. Sci Rep.
6:227932016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yu L, Gong X, Sun L, Yao H, Lu B and Zhu
L: miR-454 functions as an oncogene by inhibiting CHD5 in
hepatocellular carcinoma. Oncotarget. 6:39225–39234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wagner KU and Schmidt JW: The two faces of
Janus kinases and their respective STATs in mammary gland
development and cancer. J Carcinog. 10:322011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mora LB, Buettner R, Seigne J, Diaz J,
Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, et
al: Constitutive activation of Stat3 in human prostate tumors and
cell lines: Direct inhibition of Stat3 signaling induces apoptosis
of prostate cancer cells. Cancer Res. 62:6659–6666. 2002.PubMed/NCBI
|
|
34
|
Dolled-Filhart M, Camp RL, Kowalski DP,
Smith BL and Rimm DL: Tissue microarray analysis of signal
transducers and activators of transcription 3 (Stat3) and
phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear
localization is associated with a better prognosis. Clin Cancer
Res. 9:594–600. 2003.PubMed/NCBI
|
|
35
|
Nagpal JK, Mishra R and Das BR: Activation
of Stat-3 as one of the early events in tobacco chewing-mediated
oral carcinogenesis. Cancer. 94:2393–2400. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Song L, Turkson J, Karras JG, Jove R and
Haura EB: Activation of Stat3 by receptor tyrosine kinases and
cytokines regulates survival in human non-small cell carcinoma
cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang
X: Prognostic significance of STAT3 expression and its correlation
with chemoresistance of non-small cell lung cancer cells. Acta
Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhu BR, Cai JM, Tang GS, Li BL, Gao F, Cui
JG and Liu HC: Effects of STAT3 antisense oligonucleotide on
proliferation and apoptosis of non-small cell lung cancer cell line
A549. Ai Zheng. 26:820–827. 2007.(In Chinese). PubMed/NCBI
|
|
39
|
Siveen KS, Sikka S, Surana R, Dai X, Zhang
J, Kumar AP, Tan BK, Sethi G and Bishayee A: Targeting the STAT3
signaling pathway in cancer: Role of synthetic and natural
inhibitors. Biochim Biophys Acta. 1845:136–154. 2014.PubMed/NCBI
|
